Compass Therapeutics (NASDAQ:CMPX) Now Covered by Piper Sandler

Piper Sandler initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report issued on Wednesday morning, Marketbeat reports. The firm issued an overweight rating and a $12.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. Jefferies Financial Group boosted their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.29.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $2.92 on Wednesday. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08. The firm has a 50 day moving average price of $2.43 and a two-hundred day moving average price of $1.88. The firm has a market cap of $401.76 million, a price-to-earnings ratio of -7.89 and a beta of 1.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CMPX. Rovin Capital UT ADV purchased a new position in shares of Compass Therapeutics in the third quarter worth about $25,000. Tower Research Capital LLC TRC grew its stake in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after buying an additional 12,917 shares in the last quarter. Independent Advisor Alliance bought a new stake in Compass Therapeutics during the 4th quarter valued at $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics during the fourth quarter worth $27,000. Finally, Intech Investment Management LLC bought a new position in shares of Compass Therapeutics in the third quarter worth $30,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.